Cite
ASSOCIATION OF SODIUM/GLUCOSE COTRANSPORTER-2 INHIBITORS WITH OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND ATRIAL FIBRILLATION.
MLA
Brewerton, Annie, et al. “Association of Sodium/Glucose Cotransporter-2 Inhibitors with Outcomes in Patients with Type 2 Diabetes and Atrial Fibrillation.” Journal of the American College of Cardiology (JACC), vol. 79, no. 9, Mar. 2022, p. 1527. EBSCOhost, https://doi.org/10.1016/S0735-1097(22)02518-9.
APA
Brewerton, A., Abdel-Qadir, H. M., Ko, D. T., Lee, D., Singh, S. M. S., Jackevicius, C., Dorian, P., Austin, P., Han, L., & Lega, I. (2022). Association of Sodium/Glucose Cotransporter-2 Inhibitors with Outcomes in Patients with Type 2 Diabetes and Atrial Fibrillation. Journal of the American College of Cardiology (JACC), 79(9), 1527. https://doi.org/10.1016/S0735-1097(22)02518-9
Chicago
Brewerton, Annie, Husam Mohamed Abdel-Qadir, Dennis T. Ko, Douglas Lee, Sheldon M.S. Singh, Cynthia Jackevicius, Paul Dorian, Peter Austin, Lu Han, and Iliana Lega. 2022. “Association of Sodium/Glucose Cotransporter-2 Inhibitors with Outcomes in Patients with Type 2 Diabetes and Atrial Fibrillation.” Journal of the American College of Cardiology (JACC) 79 (9): 1527. doi:10.1016/S0735-1097(22)02518-9.